SCHEMBL23327657

SCHEMBL23327657

O=[N+]([O-])c1ccc(OCC2CCC2)c(Cl)c1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 2/20 0.54
HPGD P15428 6/20 0.51
MAPT P10636 5/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
LMNA P02545 3/20 0.51
ALDH1A1 P00352 3/20 0.51
RAB9A P51151 2/20 0.51
NPC1 O15118 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
KMT2A Q03164 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
PDE7A Q13946 1/20 0.47
HSD17B10 Q99714 1/20 0.46
CNR2 P34972 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30882122 1.00 CYP19A1 (0.54) CYP19A1HPGDMAPTSMN1; SMN2LMNA
SCHEMBL22069670 0.97 CYP19A1 (0.57) CYP19A1HPGDMAPTSMN1; SMN2LMNA
SCHEMBL2564892 0.94 MAPT (0.53) CYP19A1HPGDMAPTSMN1; SMN2LMNA
SCHEMBL30125863 0.85 MAPT (0.50) CYP19A1HPGDMAPTSMN1; SMN2LMNA
SCHEMBL30127491 0.83 MAPT (0.46) CYP19A1HPGDMAPTSMN1; SMN2LMNA
SCHEMBL10002964 0.83 CYP19A1 (0.53) CYP19A1HPGDMAPTSMN1; SMN2LMNA
SCHEMBL30125933 0.83 CYP19A1 (0.53) CYP19A1HPGDMAPTSMN1; SMN2LMNA
SCHEMBL5704493 0.82 CYP19A1 (0.59) CYP19A1HPGDMAPTSMN1; SMN2LMNA
SCHEMBL12835342 0.81 MAPT (0.51) HPGDMAPTSMN1; SMN2LMNAALDH1A1
SCHEMBL22069747 0.81 CYP19A1 (0.59) CYP19A1ALDH1A1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3820860-B1 PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 LIEBER INST INC (US) 2025-10-15 EP disclosed
US-11993581-B2 Pyridazine compounds for inhibiting Nav1.8 LIEBER INSTITUE, INC (US) 2024-05-28 US disclosed
CN-112689629-B For inhibiting Nav1.8 Pyridazine Compounds 利伯研究所公司 2024-04-23 CN disclosed
EP-3820860-A1 PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 Lieber Institute, Inc. (US) 2021-05-19 EP disclosed
US-20210139456-A1 PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 LIEBER INSTITUTE, INC 2021-05-13 US disclosed
US-20210139456-A1 PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 LIEBER INSTITUTE, INC 2021-05-13 US disclosed
CN-112689629-A For inhibiting Nav1.8 pyridazine Compounds 利伯研究所公司 2021-04-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210139456-A1 PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 SCN8A, SCN5A, SCN2A CYP19A1 4791/4885HPGD 1577/4885MAPT 1531/4885
US-11993581-B2 Pyridazine compounds for inhibiting Nav1.8 SCN8A, SCN5A, SCN2A CYP19A1 4791/4885HPGD 1577/4885MAPT 1531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.